Background and objectives:COVID-19 related inflammation, endothelial dysfunction and coagulopathy may increase the bleeding risk and lower efficacy of revascularization treatments in patients with acute ischemic stroke. We aimed to evaluate the safety and outcomes of revascularization treatments in patients with acute ischemic stroke and COVID-19.Methods:Retrospective multicenter cohort study of consecutive patients with acute ischemic stroke receiving intravenous thrombolysis (IVT) and/or endovascular treatment (EVT) between March 2020 and June 2021, tested for SARS-CoV-2 infection. With a doubly-robust model combining propensity score weighting and multivariate regression, we studied the association of COVID-19 with intracranial bleeding complications and clinical outcomes. Subgroup analyses were performed according to treatment groups (IVT-only and EVT).Results:Of a total of 15128 included patients from 105 centers, 853 (5.6%) were diagnosed with COVID-19. 5848 (38.7%) patients received IVT-only, and 9280 (61.3%) EVT (with or without IVT). Patients with COVID-19 had a higher rate of symptomatic intracerebral hemorrhage (SICH) (adjusted odds ratio [OR] 1.53; 95% CI 1.16–2.01), symptomatic subarachnoid hemorrhage (SSAH) (OR 1.80; 95% CI 1.20–2.69), SICH and/or SSAH combined (OR 1.56; 95% CI 1.23–1.99), 24-hour (OR 2.47; 95% CI 1.58–3.86) and 3-month mortality (OR 1.88; 95% CI 1.52–2.33).COVID-19 patients also had an unfavorable shift in the distribution of the modified Rankin score at 3 months (OR 1.42; 95% CI 1.26–1.60).Discussion:Patients with acute ischemic stroke and COVID-19 showed higher rates of intracranial bleeding complications and worse clinical outcomes after revascularization treatments than contemporaneous non-COVID-19 treated patients. Current available data does not allow direct conclusions to be drawn on the effectiveness of revascularization treatments in COVID-19 patients, or to establish different treatment recommendations in this subgroup of patients with ischemic stroke. Our findings can be taken into consideration for treatment decisions, patient monitoring and establishing prognosis.

Aim of study. Mechanical thrombectomy (MT) is one of the aetiological treatment options recommended for anticoagulated patients with acute ischaemic stroke (AIS). We analysed its long-term outcomes using the modified Rankin Score (mRS) or mortality on day 90.Clinical rationale for the study. Data describing the anticoagulant efficacy and safety of MT in patients with AIS is limited.Materials and methods. This study included 291 patients with AIS (49% women, mean [SD] age 66 [15] years) who underwent MT in the Comprehensive Stroke Centre in Krakow, Poland. Data describing demographics, stroke risk factors, NIHSS on admission, postprocedural thrombolysis in cerebral infarction score, 24-hour postprocedural haemorrhagic transformation (ECASS-2) as seen on computed tomography, and time between stroke onset and groin puncture was collected. The outcome measure was the mRS on day 90 after stroke onset (a favourable outcome was defined as an mRS not exceeding 2 points; an unfavourable outcome was death).Results. Thirty-seven patients (13%) were on therapeutic anticoagulation during MT. Univariate analysis showed that anticoagulated patients were older and more likely to have been diagnosed with hypertension, ischaemic heart disease, or atrial fibrillation. The patient groups did not differ in terms of clot location, postprocedural thrombolysis in cerebral infarction score, haemorrhagic transformation on computed tomography, or mRS on day 90. Multivariate logistic regression analysis showed that younger age, male sex, no history of diabetes mellitus, lower NIHSS score on admission, shorter time between stroke onset and groin puncture, and better recanalisation were associated with favourable outcomes at day 90, and that therapeutic anticoagulation was not (OR, 1.00; 95%CI, 0.46-2.15; p = 0.99). Anticoagulation did not affect mortality at day 90 (OR, 1.28; 95%CI, 0.56-2.92; p = 0.55). Conclusion and clinical implications.In anticoagulated patients with AIS, MT does not affect long-term outcomes.

Związek Friends with Benefits (FWB) (w dosłownym tłumaczeniu „przyjaciele z korzyścią/bonusem”) to relacja, w której przyjaciele utrzymują ze sobą powtarzalne kontakty seksualne, wykluczająca jednak romantyczne zaangażowanie. Badania skupiły się na wybranych aspektach związków Friends with Benefits, należą do nich: rozpowszechnienie omawianych związków, motywy, oczekiwania i charakterystyka ich uczestników. Badania miały na celu określić różnice w sposobie, w jaki mężczyźni i kobiety nawiązują „przyjaźń z bonusem”. W tym celu przeprowadzono za pośrednictwem Internetu badania wśród osób zaangażowanych obecnie w relacje FWB (łącznie 134 osoby, w tym 65 mężczyzn i 65 kobiet). Wyniki wskazują na wiele podobieństw, ale także różnic, bowiem seks był częściej wymienianym motywem do rozpoczęcia takich relacji przez mężczyzn, podczas gdy motywy emocjonalne i seksualne w równym stopniu motywowały kobiety. Związki te postrzegane są jako nowość w dziedzinie relacji międzyludzkich, a w szczególności w obszarze polskich badań, i wymagają dalszej eksploracji.

MNS amp and NMR were significantly reduced when compared to controls (p b 0.0001), whereas MNS lat and NMD were increased (p = 0.0049; see Fig. 1). ConclusionsCOVID patients suffered from a critical illness neuropathy (CIP), differently from the previous literature showing a higher prevalence of myopathy in non-COVID ICU patients. That could have implications for the functional recovery and rehabilitation strategies of COVID patients, thus delaying ICU discharge, also highlighting novel insights into the neuropathology of COVID-19.